Zobrazeno 1 - 10
of 79
pro vyhledávání: '"A. O. BUEVEROV"'
Autor:
P. O. Bogomolov, N. A. Shub, N. A. Gasilova, A. A. Belyakova, T. G. Lidzhieva, E. A. Kondrasheva, N. A. Barsukova, M. V. Arapova, E. A. Isaeva, S. V. Koblov, M. V. Kalashnikov, O. S. Kuzymina, A. Yu. Demyanov, A. O. Bueverov, I. V. Maev
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 5, Pp 40-46 (2024)
Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of in
Externí odkaz:
https://doaj.org/article/93bd69b322bc469fbdc26ae6022e8f8c
Autor:
K. L. Raikhelson, A. O. Bueverov, E. A. Kondrashina, M. V. Maevskaya, I. B. Khlynov, E. N. Shirokova, V. T. Ivashkin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 4, Pp 20-33 (2024)
Aim: to analyse the principles of diagnosis and treatment of intrahepatic cholestasis in chronic liver diseases, to present data on the effectiveness of ademetionine in the treatment of chronic liver diseases with intrahepatic cholestasis and the mat
Externí odkaz:
https://doaj.org/article/0301d95bd7c647e7b8f7a943a69a5990
Publikováno v:
Журнал инфектологии, Vol 16, Iss 2, Pp 46-51 (2024)
Substantiation: Monitoring adverse events (AEs) among outpatients is an important clinical problem; as they may be the cause of treatment interruption. In this situation; using telemedicine technologies (TMT) is rational to prevent these events and e
Externí odkaz:
https://doaj.org/article/40b4b690e8a44694aca228ea2b9f4a76
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 1, Pp 31-36 (2024)
Aim of the study: evaluate the role of normalization of humoral immunity to address dose reduction or discontinuation of immunosuppressors in patients with autoimmune hepatitis (AIH).Patients and methods. The data of 47 patients with AIH who received
Externí odkaz:
https://doaj.org/article/2450f56f13744854aa9fb1f4c455a033
Autor:
M. Yu. Nadinskaia, M. V. Maevskaya, I. G. Bakulin, E. N. Bessonova, A. O. Bueverov, M. S. Zharkova, S. V. Okovityi, A. S. Ostrovskaya, K. A. Gulyaeva, V. T. Ivashkin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 1, Pp 85-100 (2024)
Introduction. In cirrhotic patients, hyperammonemia develops due to impaired ammonia detoxification and portosystemic blood shunting and is most commonly associated with hepatic encephalopathy and sarcopenia. Currently, there are questions regarding
Externí odkaz:
https://doaj.org/article/7401b7a6adbb44e08730d84f62720d91
Autor:
A. O. Bueverov
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 68-76 (2021)
The relationship between metabolic non-alcoholic fatty liver disease (NAFLD) and gallstone disease (GSD) is complex and seemingly interrelated. There is no doubt that there is an increased risk of cholelithiasis in patients with NAFLD, which is prima
Externí odkaz:
https://doaj.org/article/811f7794f4624086a3489d10a03e109e
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 88-94 (2021)
Thyroid gland (TG) and the liver are in a complex relationship in both physiological and pathological conditions. Thyroid hormones accelerate metabolic processes, intensify the synthesis of proteins and vitamins, play an important role in the develop
Externí odkaz:
https://doaj.org/article/9a2459a8413b44b297a5535a13fdb4ee
Autor:
A. O. Bueverov, A. V. Zilov
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 31, Iss 2, Pp 7-13 (2021)
Aim. An up-to-date review of the prevalence, pathogenesis, diagnosis and management of hepatological complications of type 1 diabetes mellitus (T1D).Key points. Diabetes type 1 causes a markedly more common liver injury than traditionally assumed. Th
Externí odkaz:
https://doaj.org/article/97ae0ad15c7748dbbe3587d94b01b5f7
Publikováno v:
Сеченовский вестник, Vol 11, Iss 4, Pp 15-22 (2020)
Aim. Evaluation of efficacy and safety of alirocumab in patients with atherogenic dyslipidemia in real clinical practice.Materials and methods. Patients with atherogenic dyslipidemia and failure to achieve target lipid levels were included in a prosp
Externí odkaz:
https://doaj.org/article/10ec8549dc694eed872a0400b34e4451
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 30, Iss 4, Pp 23-27 (2020)
Bulevirtide is a novel antiviral agent approved for suppression of chronic hepatitis D but requiring further research into optimising the treatment scheme.Aim. Comparative assessment of bulevirtide monotherapy versus combined treatment with bulevirti
Externí odkaz:
https://doaj.org/article/5c7cea1ecfde486d9d0d1a645dc0ad7e